Bayer Aktiengesellschaft

Wayne State University

Baker Aktiengesellshaft

Friedel Seuter

Elisabeth Perzborn

Ulrich Rosentreter

Horst Boshagen

Volker-Bernd Fiedler

Folker Lieb

Eike Moller

Hermann Oediger

Harald Horstmann

Egbert Wehinger

Karl-August Meng, Deceased

Ulrich Niewohner

Franz-Peter Hoever

Gerhard Franckowiak

Michael Kayser

Mithat Mardin

Ulrich Horlein

Volker Fiedler

Dieter Mayer

Rainer Gross

Matthias Schramm

Romanis Fruchtmann

Christian Kohlsdorfer

Klaus Mohrs

Klaus Schlossmann

Gunther Thomas

Wolf-Dieter Busse

Karl Meng, Deceased

Bodo Junge

Martin Bechem

Friedrich Hoffmeister

Horst Meyer

Klaus Sasse

Klaus Schaller

Hans-Joachim Kabbe

Walter Puls

Gunter Thomas

Trevor S Abram

Kenneth V Honn

Graham Sturton

Bernhard Pelster

Gerd Reinhardt

Joachim Ippen

Hartmut Stegelmeier

By Matthias Meng, Legal Representative

Michael Hammond

New phenylsulphonamide of the formula in which ##STR1## R.sup.1 represents a pyridyl, quinolyl or isoquinolyl radical which is unsubstituted or substituted by halogen, alkyl, cycloalkyl, alkoxy, cyano, nitro, halogenoalkyl, halogenoalkoxy, alkoxycarbonyl or alkylsulphonyl,

Antiflammatory quinolin methoxy phenylsulphonamides

New phenylsulphonamides of the formula in which ##STR1## R.sup.1 represents a pyridyl, quinolyl or isoquinolyl radical which is unsubstituted or substituted by halogen, alkyl, cycloalkyl, alkoxy, cyano, nitro, halogenoalkyl, halogenoalkoxy, alkoxycarbonyl or alkylsulphonyl,

Substituted phenylsulphonamides

Quinolinoxy phenylsulphonamides

Cycloalkano[1,2-b]indole-sulphonamides of the formula ##STR1## in which R.sup.1 represents hydrogen, halogen, trifluoromethyl, carboxyl or alkoxycarbonyl, represents a group of the formula --S(O).sub.m R.sup.3, in which R.sup.3 denotes alkyl or aryl, and m denotes one of the numbers 0, 1 or 2, represents a group of the formula ##STR2## in which R.sup.4 and R.sup.5 are identical or different and represent hydrogen, alkyl, aryl, aralkyl or acetyl, represents a group of the formula --OR.sup.6, in which R.sup.6 denotes hydrogen, alkyl, aryl, aralkyl, alkyl-SO.sub.2 --, aryl--SO.sub.2 --, aralkyl--SO.sub.2 -- or trifluoromethyl, or represents alkyl, alkenyl or cycloalkyl, each of which is optionally substituted by carboxyl, alkoxycarbonyl, halogen, hydroxyl, alkoxy, alkylthio or cyano, R.sup.2 represents aryl which is optionally substituted up to 5 times by halogen, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, alkylthio, hydroxyl, carboxyl, alkoxycarbonyl, phenyl, phenoxy, benzyloxy, benzylthio or a group of the formula ##STR3## in which R.sup.4 and R.sup.5 have the abovementioned meaning, x represents the number 1, 2 or 3, and y represents the number 0 or 1, where appropriate in an isomeric form, and their salts are disclosed. These compounds are useful to inhibit platelet aggregation and to antagonize thromboxane A.sub.2.

Cycloalkano(1,2-B) indole-sulponamides

Cycloalkano[1,2-b]indole-sulphonamides of the formula ##STR1## where appropriate in an isomeric form, and their salts are disclosed. These compounds are useful to inhibit platelet aggregation and to antoganize thromboxane A.sub.2.

Cycloalkano(1,2-B)indole-sulphonamides, pharmaceutical compositions and

Antithrombotic, antiatherosclerotic and antiischaemic compounds of the formula ##STR1## in which R.sup.1 is ##STR2## or SO.sub.2 R.sup.4, R.sup.3 is aryl, substituted aryl, heteroaryl, aralkyl or the group ##STR3## R.sup.4 is aryl or substrituted aryl, R.sup.2 is OH, alkoxy, phenoxy, benzoxy or NR.sup.5 R.sup.6, and

Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, processes

Cycloalkano[1,2-b]indole-sulphonamides of the formula ##STR1## where appropriate in an isomeric form, and their salts are disclosed. These compounds are useful to inhibit platelet aggregation and to antagonize thromboxane A.sub.2.

Process of preparing cycloalkano(1,2-B)indole-sulphonamides

Circulation active nitrodihydropyridines of the formula ##STR1## in which R represents aryl which has 6 to 12 carbon atoms and can be substituted up to 4 times, identically or differently, by halogen, nitro, cyano, alkyl, alkoxy, alkylthio, in each case having up to 6 carbon atoms, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylenedioxy, trifluoroethylenedioxy or tetrafluoroethylenedioxy or by benzyl, benzyloxy or benzylthio, each of which is optionally substituted by halogen, nitro, cyano, trifuoromethyl, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms, or represents a heterocycle which is optionally substituted by halogen, phenyl or alkyl having up to 4 carbon atoms and is from the group consisting of pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl, and

[4-(6-Oxo-1,4,5,6-tetrahydro-3-pyridazinyl) anilino hexyl

Certain intermediate aminomethyl-5,6,7,8-tetrahydronaphthyl-oxyacetic acid derivatives of the formula ##STR1## in which R.sup.2 is hydroxyl, alkoxy, phenoxy, benzoxy or NR.sup.4 R.sup.5, and

Intermediates for circulation-active substituted

For inhibiting thombocyte aggregation, vasodilating and bronchodilating, the new chroman derivatives of the formula ##STR1## in which R.sup.1 stands for hydrogen, halogen, alkyl, hydroxyl, alkoxy, trifluoromethyl or cyano,

Chroman derivatives for combating thrombosis and asthma

For the treatment of circulation disorders, the novel 5-nitro-1,4-dihydropyridines of the formula ##STR1## in which R represents C.sub.6 -C.sub.14 -aryl which can be mono- to pentasubstituted by identical or different substituents from the series comprising halogen, nitro, cyano, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio and benzyl, benzyloxy or benzylthio optionally substituted by nitro, cyano, trifluoromethyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, or

Circulation-active substituted 5-nitro-1,4-dihydropyridines

For the control of coronary diseases and thromboses there are provided the novel compounds ##STR1## in which R.sup.1 is an optionally substituted phenyl or heterocyclic radical,

Substituted 1,4-dihydropyridines for control of circulation and

An aminomethyl-5,6,7,8-tetrahydronaphthyl-oxyacetic acid derivative of the formula ##STR1## in which R.sup.3 is aryl or substituted aryl,

Circulation-active novel substituted

Antithrombotic, antiatherosclerotic and antiischaemic compounds of the formula ##STR1## in which R.sup.1 is ##STR2## or SO.sub.2 R.sup.4, R.sup.3 is aryl, substituted aryl, heteroaryl, aralkyl or the group ##STR3## R.sup.4 is aryl or substituted aryl, R.sup.2 is OH, alkoxy, phenoxy, benzoxy or NR.sup.5 R.sup.6, and

Thrombocyte aggregation-inhibiting polyhydrobenz[c,d]indolesulphonamide of the formula ##STR1## in which R.sup.1 is hydrogen, aryl or alkyl,

Polyhydrobenzi[c,d]indolesulphonamides

Growing community of inventors

Wuppertal, Germany

Friedel Seuter